ATE480243T1 - Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems - Google Patents

Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems

Info

Publication number: ATE480243T1
Authority: AT; Austria
Prior art keywords: useful; cns; acute; diagnosis; composition
Prior art date: 2004-06-23

Application number

AT05764495T

Other languages

English (en)

Inventor

Gehenne Josette-Nicole Mahy

Allue Manuel Jose Rodroeguez

Marco Pugliese

Original Assignee

Neurotec Pharma S L

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-23

Filing date

2005-06-23

Publication date

2010-09-15

2005-06-23 Application filed by Neurotec Pharma S L filed Critical Neurotec Pharma S L

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE480243T1 publication Critical patent/ATE480243T1/de

Links

210000003169 central nervous system Anatomy 0.000 title abstract 3
230000001154 acute effect Effects 0.000 title abstract 2
208000001738 Nervous System Trauma Diseases 0.000 title 1
238000003745 diagnosis Methods 0.000 title 1
230000009692 acute damage Effects 0.000 abstract 2
208000015114 central nervous system disease Diseases 0.000 abstract 2
230000006378 damage Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
208000027418 Wounds and injury Diseases 0.000 abstract 1
230000001363 autoimmune Effects 0.000 abstract 1
230000003376 axonal effect Effects 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
229940039227 diagnostic agent Drugs 0.000 abstract 1
239000000032 diagnostic agent Substances 0.000 abstract 1
229960004580 glibenclamide Drugs 0.000 abstract 1
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
230000002458 infectious effect Effects 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
230000002025 microglial effect Effects 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
230000001067 neuroprotector Effects 0.000 abstract 1
230000000069 prophylactic effect Effects 0.000 abstract 1
208000020431 spinal cord injury Diseases 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
230000000472 traumatic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

AT05764495T 2004-06-23 2005-06-23 Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems ATE480243T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200401628		2004-06-23
PCT/ES2005/000357 WO2006000608A1 (es)	2004-06-23	2005-06-23	Uso de bloqueantes del canal de katp (kcc), en especial sulfonilureas como la glibenclamida, para el tratamiento del daño agudo del sistema nervioso central causado por distintas enfermedades

Publications (1)

Publication Number	Publication Date
ATE480243T1 true ATE480243T1 (de)	2010-09-15

Family

ID=35781576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05764495T ATE480243T1 (de)	2004-06-23	2005-06-23	Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems

Country Status (9)

Country	Link
US (1)	US20070203239A1 (de)
EP (1)	EP1782815B1 (de)
JP (1)	JP2008503549A (de)
AT (1)	ATE480243T1 (de)
AU (1)	AU2005256676A1 (de)
CA (1)	CA2571718A1 (de)
DE (1)	DE602005023489D1 (de)
ES (1)	ES2352203T3 (de)
WO (1)	WO2006000608A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8980952B2 (en) *	2002-03-20	2015-03-17	University Of Maryland, Baltimore	Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP2438913B1 (de)	2002-03-20	2020-05-06	University of Maryland, Baltimore	Nicht-selektiver Kationenkanal in neuralen Zellen und Verfahren zur Behandlung von Hirnschwellung
CA2580606A1 (en)	2004-09-18	2006-03-30	University Of Maryland, Baltimore	Therapeutic agents targeting the ncca-atp channel and methods of use thereof
CN101043891A (zh)	2004-09-18	2007-09-26	巴尔的摩马里兰大学	靶向NCCa－ATP通道的治疗剂及其使用方法
EP1884244A1 (de)	2006-08-02	2008-02-06	Assistance Publique - Hopitaux de Paris	Kalium-Kanal Liganden zur Behandlung von Diabetes und neuropsychologischen Störungen
CA2674949A1 (en)	2007-01-12	2008-07-24	J. Marc Simard	Targeting ncca-atp channel for organ protection following ischemic episode
WO2008098160A1 (en) *	2007-02-09	2008-08-14	University Of Maryland, Baltimore	Antagonists of a non-selective cation channel in neural cells
EP2167107B1 (de)	2007-06-22	2016-12-14	University of Maryland, Baltimore	Inhibitoren von ncca-atp-kanälen zur therapie
US9662347B2 (en)	2010-05-11	2017-05-30	Gachon University Of Industry-Academic Cooperation Foundation	Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
EP2609914A1 (de) *	2011-12-29	2013-07-03	Universitätsklinikum Hamburg-Eppendorf	Neue Verfahren zur Behandlung oder Vermeidung von Neurodegeneration
US10058542B1 (en)	2014-09-12	2018-08-28	Thioredoxin Systems Ab	Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4444860A1 (de) *	1994-12-16	1996-06-20	Bayer Ag	Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als Arzneimittel
US6147098A (en) *	1998-05-11	2000-11-14	Novo Nordisk A/S	Substituted guanidines and diaminonitroethenes, their preparation and use
US20030045449A1 (en) *	2001-08-15	2003-03-06	Pfizer, Inc.	Pharmaceutical combinations for the treatment of neurodegenerative diseases
US8980952B2 (en) *	2002-03-20	2015-03-17	University Of Maryland, Baltimore	Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP2438913B1 (de) *	2002-03-20	2020-05-06	University of Maryland, Baltimore	Nicht-selektiver Kationenkanal in neuralen Zellen und Verfahren zur Behandlung von Hirnschwellung
WO2004093896A1 (en) *	2003-04-22	2004-11-04	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
WO2004093816A2 (en) *	2003-04-22	2004-11-04	Pharmacia Corporation	Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
WO2004093811A2 (en) *	2003-04-22	2004-11-04	Pharmacia Corporation	Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
JP2007505142A (ja) *	2003-09-10	2007-03-08	セダーズ−シナイメディカルセンター	血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
CA2580606A1 (en) *	2004-09-18	2006-03-30	University Of Maryland, Baltimore	Therapeutic agents targeting the ncca-atp channel and methods of use thereof

2005
- 2005-06-23 US US11/630,420 patent/US20070203239A1/en not_active Abandoned
- 2005-06-23 EP EP05764495A patent/EP1782815B1/de not_active Expired - Lifetime
- 2005-06-23 CA CA002571718A patent/CA2571718A1/en not_active Abandoned
- 2005-06-23 DE DE602005023489T patent/DE602005023489D1/de not_active Expired - Lifetime
- 2005-06-23 AU AU2005256676A patent/AU2005256676A1/en not_active Abandoned
- 2005-06-23 JP JP2007517311A patent/JP2008503549A/ja not_active Withdrawn
- 2005-06-23 AT AT05764495T patent/ATE480243T1/de not_active IP Right Cessation
- 2005-06-23 ES ES05764495T patent/ES2352203T3/es not_active Expired - Lifetime
- 2005-06-23 WO PCT/ES2005/000357 patent/WO2006000608A1/es not_active Ceased

Also Published As

Publication number	Publication date
AU2005256676A1 (en)	2006-01-05
EP1782815B1 (de)	2010-09-08
DE602005023489D1 (de)	2010-10-21
WO2006000608A1 (es)	2006-01-05
CA2571718A1 (en)	2006-01-05
US20070203239A1 (en)	2007-08-30
ES2352203T3 (es)	2011-02-16
JP2008503549A (ja)	2008-02-07
EP1782815A1 (de)	2007-05-09

Similar Documents

Publication	Publication Date	Title
GB0421639D0 (en)	2004-10-27	Methods and compositions relating to alzheimer's disease
IL225192A (en)	2017-12-31	Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
DK1409544T3 (da)	2009-10-26	Humane DR4-antistoffer og anvendelser deraf
WO2004037204A3 (en)	2006-05-26	Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
ATE413902T1 (de)	2008-11-15	Patientenüberwachungssystem
AU2002303295B2 (en)	2006-11-30	Diagnosis and treatment of neural disease and injury using microvoltammetry
EP2006298A3 (de)	2009-04-22	Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon
SI1615952T1 (sl)	2012-03-30	Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin
ATE480243T1 (de)	2010-09-15	Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems
PT1163904E (pt)	2006-07-31	Composicao para a prevencao de doencas do musculo liso, compreendendo ascorbato, arginina e magnesio
BRPI0407662B8 (pt)	2021-05-25	derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
DE602007000529D1 (de)	2009-03-26	Aktives medizinisches Implantat, insbesondere Vorrichtung zur Stimulation, Resynchronisation, Defibrillation und/oder Kardioversion, die Mittel zur prädiktiven Warnung über eine Verschlimmerung des Krankheitszustands des Patienten umfasst
IL181286A0 (en)	2007-07-04	Methods of healing wounds by administering human il-18
WO2005012330A3 (en)	2005-09-09	AMYLOID β-PEPTIDE AND METHODS OF USE
WO2007112355A3 (en)	2007-12-06	Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders
WO2007133746A3 (en)	2008-03-20	Use of nogo receptor-1 (ngr1) antagonists for promoting oligodendrocyte survival
ATE453627T1 (de)	2010-01-15	Herstellung von verbindungen zur bestimmung der hypoxie
DE602008004556D1 (de)	2011-02-24	Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
ATE553763T1 (de)	2012-05-15	Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern
WO2002062205A3 (en)	2003-09-12	Methods for diagnosing and treating heart disease
SI1596879T1 (sl)	2011-07-29	Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
EP2096120A3 (de)	2009-12-02	Verwendung sekretierter Proteinprodukte zur Prävention und Behandlung von Erkrankungen der Bauchspeicheldrüse und/oder Adipositas und/oder des metabolischen Syndroms
WO2002062300A3 (en)	2002-10-24	Cholesterol-lowering agents as treatment for psychological and cognitive disorders
WO2003001877A3 (en)	2003-09-12	Methods for the diagnosis and treatment of cardiac tissue rejection
WO2003028536A3 (en)	2003-11-13	Methods for diagnosing and treating heart disease

Legal Events

Date	Code	Title	Description
2011-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties